Sermorelin

Sermorelin is a synthetic 29-amino acid peptide representing the biologically active N-terminal fragment of growth hormone-releasing hormone (GHRH), the naturally occurring hypothalamic peptide that stimulates the anterior pituitary to produce and secrete human growth hormone (hGH). The full-length GHRH contains 44 amino acids, but research demonstrated that the first 29 are sufficient for full biological activity at the GHRH receptor, making sermorelin a compact and functionally complete analogue. Sermorelin was FDA-approved in 1997 (brand name Geref) for the treatment of growth hormone deficiency in children with idiopathic growth failure, and it was also approved for use as a diagnostic test of pituitary GH reserve.

The mechanism of action of sermorelin is categorically different from direct growth hormone replacement therapy. Exogenous recombinant human GH (rhGH) bypasses the pituitary entirely, delivering preformed GH directly into the circulation. This approach suppresses the hypothalamic-pituitary axis, creates supraphysiological GH peaks, and requires continuous administration to maintain effects. Sermorelin, by contrast, binds to the GHRH receptor on pituitary somatotroph cells, stimulating these cells to synthesize and release the body's own endogenous GH in a pulsatile, physiologically regulated manner. Because sermorelin's effects are subject to normal negative feedback via somatostatin (the hypothalamic GH-inhibitory hormone), it is pharmacologically very difficult to overdose. The pituitary remains in control of ultimate GH output, preserving the natural pulsatile secretion pattern that recombinant GH cannot replicate.

Published clinical evidence for sermorelin is substantial relative to many research peptides. A 1996 study demonstrated that daily sermorelin injection increased height velocity in 74 percent of GH-deficient children within 6 months. Significant increases in height velocity were maintained through 12 months and in a subset of children through 36 months of continued treatment. The 1999 publication by Alba et al. confirmed that sermorelin successfully stimulated growth in the majority of GH-deficient children treated. Importantly, sermorelin also stimulates the production of insulin-like growth factor 1 (IGF-1) from the liver, and IGF-1 is thought to mediate many of GH's anabolic and metabolic effects, including lean mass accretion, fat metabolism, bone density, and tissue repair. The FDA discontinued the commercial product in 2008 for economic reasons (not safety), and sermorelin currently exists as a compounded pharmaceutical available through licensed compounding pharmacies with a valid prescription.

Off-label use of sermorelin in adults has expanded significantly in the context of age-related growth hormone decline. GH secretion decreases by roughly 14 percent per decade after peak secretion in young adulthood. Adult users of sermorelin report gradual improvements in body composition, sleep quality (GH is predominantly secreted during slow-wave sleep), energy, skin texture, and recovery from exercise over courses of 3-6 months. Results are generally slower and more modest than with direct GH replacement but without the associated risks of receptor downregulation or supraphysiological exposure.